Fosun Pharma to accelerate A-share repurchase program
Shanghai Fosun Pharmaceutical Group (SSE:600196) announced it will accelerate its A-share repurchase program, initially approved on January 22, 2025. The company aims to boost investor confidence and safeguard shareholder interests. The repurchase program, conducted through centralized bidding, involves a total repurchase amount of between CNY300 million and CNY600 million, with a repurchase price ceiling of CNY30 per share. As of March 31, 2025, Fosun Pharma had already repurchased 1,613,300 A-shares, representing approximately 0.0604% of the company's total share capital, for a total of CNY3,999.41 million (excluding transaction costs). The company will disclose information about the repurchase progress in a timely manner, in accordance with relevant regulations, including the "Rules for Stock Repurchase of Listed Companies" and the "Self-Regulation Guidelines for Listed Companies of the Shanghai Stock Exchange No. 7—Repurchase of Shares".
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime